Scientist, Zymo Research Corporation, DE

BIO

Summary:

  • 10+ years of experience in cancer & epigenetics research, drug discovery, large scale date analysis, translational medicine;
  • Strong academic and technical background in cellular and molecular biology, pharmacology and biotechnology;
  • Expertise in strategy development, design, management and timely execution of research projects;
  • Impressive publication record in leading scholarly journals, including 3 Cancer Cell papers

Professional Experience  

Zymo Research                                                                                          2015- present

Scientist

  • Leading and driving research and development of high-plex target enrichment platforms
  • Developed an epigenetic based bladder cancer recurrence test using urine sample.
  • Contributed in development of innovated clinical tests and veterinary tests.

University of Southern California                                                               2009-2015

Postdoctoral Research Associate                                  Supervisor: Dr. Peter A. Jones

  • Identified gene body methylation as a therapeutic target in cancer
  • Elucidated the function of H2A.Z in 5-Aza-2’-deoxycytine (Decitabine) induced gene reactivation process
  • Developed a novel prognostic marker (VTRNA2-1) for AML patients by collaborating with clinical physicians.
  • Developed new non-invasive bio-markers for monitoring  patients’ responses to demethylation drugs by screening DNA methylation changes in patients’ samples
  • Developed a novel assay to detect global chromatin architecture
  • Investigated  epigenetic signatures of genes with non-CpG island promoters
  • Tested  and analyzed global effects of combinatorial treatments consisting of Decitabine and EZH2 inhibitors or LSD1 inhibitors
  • Screened panels of potential DNA demethylation agents

Genome Institute of Singapore                                                                       2005-2009

Ph.D. Student/ Postdoctoral Fellow                                                

  • Established a high throughput drug screening platform based on the Rb/E2F1 pathway
  • Identified the anticancer activity of NSC 617989 (DZNep)
  • Characterized DZNep as the first epigenetic drug targeting Polycomb group proteins
  • Investigated the function of miR-449a/b in cell cycle regulation and tumorogenesis.
  • Discovered  a novel epigenetic repression mechanism for CDKN1C
  • Identified DACT3 as a novel epigenetic regulator of Wnt/β-Catenin signaling in cancer cells
  • Studied the ribosomal protein S27-like(RPS27L) function in p53 signaling pathway

EDUCATION

Peking Union Medical College 

Ph.D. Equivalent to Pharmacology in U.S. degree evaluation                        2003- 2008

Peking University                       

BS     Pharmaceutical Sciences                                                                         1999-2003                                                                                                                                                                                      

MORE INFO

Zymo research website

Speaker at
20 - 21 March 2017, Antwerp, Belgium